Immusoft, Takeda ink metabolic disorder cell therapy deal

By The Science Advisory Board staff writers

Immusoft has signed a research and licensing deal with Takeda Pharmaceutical to develop cell therapies for rare inherited metabolic disorders that have manifestations in the central nervous system.

The collaboration will focus on delivering protein therapeutics across the blood-brain barrier. Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million.

Immusoft is eligible for tiered royalties on future products resulting from the partnership, and Takeda would be responsible for further preclinical and clinical development and commercialization.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking